KR20040066892A - 치료 방법 - Google Patents
치료 방법 Download PDFInfo
- Publication number
- KR20040066892A KR20040066892A KR10-2004-7009000A KR20047009000A KR20040066892A KR 20040066892 A KR20040066892 A KR 20040066892A KR 20047009000 A KR20047009000 A KR 20047009000A KR 20040066892 A KR20040066892 A KR 20040066892A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutically acceptable
- overactive bladder
- patients
- acceptable derivative
- darfenacin
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 6
- 206010020853 Hypertonic bladder Diseases 0.000 claims abstract description 38
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims abstract description 38
- 208000020629 overactive bladder Diseases 0.000 claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 3
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 claims description 10
- 229960002677 darifenacin Drugs 0.000 claims description 9
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical group Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 238000013268 sustained release Methods 0.000 claims description 3
- 239000012730 sustained-release form Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 claims description 2
- 239000013563 matrix tablet Substances 0.000 claims 1
- 239000000902 placebo Substances 0.000 description 15
- 229940068196 placebo Drugs 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 8
- 206010046543 Urinary incontinence Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 5
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- -1 2,3-dihydrobenzofuran-5-yl Chemical group 0.000 description 1
- 206010005052 Bladder irritation Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Chemical Treatment Of Metals (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Processing Of Meat And Fish (AREA)
- Document Processing Apparatus (AREA)
- Inorganic Insulating Materials (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
Abstract
Description
요급의 발생수/일 | 위약 | 7.5 ㎎ | l5 ㎎ | 30 ㎎ |
기준점 | 8.1 | 8.5 | 8.6 | 8.4 |
기준점으로부터 중간값 변화 | -1.2 | -1.8 | -2.3* | -3*** |
기준점으로부터 중간값 % 변화 | -15.7 | -29.2 | -26.9 | -33.1 |
요급의 심각도/일 | 위약 | 7.5 ㎎ | 15 ㎎ | 30 ㎎ |
기준점 | 53.5 | 53.2 | 56.2 | 53.5 |
기준점으로부터 중간값 변화 | -3.9 | -7 | -7* | -9.4* |
기준점으로부터 중간값 % 변화 | -8.0 | -14.2 | -11.6 | -19.9 |
요급의 발생수/일 | 7.5 ㎎ | l5 ㎎ | 30 ㎎ |
기준점 | 8.5 | 8.6 | 8.4 |
위약의 중간값 차이 | -0.5 | -1.1* | -1.4*** |
요급의 심각도/일 | 7.5 ㎎ | l5 ㎎ | 30 ㎎ |
기준점 | 53.2 | 56.2 | 53.5 |
위약의 중간값 차이 | -2.5 | -3.8* | -5.5* |
경고 시간 (분) | 다리페나신 | 위약 |
기준점 (중간값) | 4.7 | 9.4 |
2 주 (중간값) | 8.4** | 4.1 |
Claims (9)
- 다리페나신 또는 그의 제약학적으로 허용되는 유도체의, 과민성 방광으로 고통받는 환자의 요급 (urgency)을 감소시키는 의약 제조에서의 용도.
- 제1항에 있어서, 다리페나신이 제약학적으로 허용되는 산 부가염의 형태인 용도.
- 제1항에 있어서, 다리페나신이 그의 브롬화수소산염 형태인 용도.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 치료 환자가 습성 (wet) 과민성 방광으로 고통받는 것인 용도.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 치료 환자가 건성 (dry) 과민성 방광으로 고통받는 것인 용도.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 다리페나신 또는 그의 제약학적으로 허용되는 유도체가 환자의 하부 위장관에서 10 % 이상의 다리페나신 또는 그의 제약학적으로 허용되는 유도체를 방출하도록 조절된 투여 형태로 투여되는 용도.
- 제6항에 있어서, 투여 형태가 서방형 매트릭스 정제인 용도.
- 과민성 방광으로 고통받는 환자의 요급의 감소에 사용하기 위한 다리페나신 또는 그의 제약학적으로 허용되는 유도체.
- 다리페나신 또는 그의 제약학적으로 허용되는 유도체를 과민성 방광의 치료가 필요한 환자에게 투여하는 것을 포함하는, 과민성 방광으로 고통받는 환자의 요급을 감소시키는 방법.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0129962.7A GB0129962D0 (en) | 2001-12-14 | 2001-12-14 | Method of treatment |
GB0129962.7 | 2001-12-14 | ||
PCT/IB2002/000664 WO2003051354A1 (en) | 2001-12-14 | 2002-03-05 | Method of treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040066892A true KR20040066892A (ko) | 2004-07-27 |
KR100889086B1 KR100889086B1 (ko) | 2009-03-16 |
Family
ID=9927643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047009000A KR100889086B1 (ko) | 2001-12-14 | 2002-03-05 | 치료 방법 |
Country Status (28)
Country | Link |
---|---|
US (3) | US20030130338A1 (ko) |
EP (1) | EP1458376B1 (ko) |
JP (3) | JP2005516925A (ko) |
KR (1) | KR100889086B1 (ko) |
CN (1) | CN100488505C (ko) |
AT (1) | ATE341323T1 (ko) |
AU (1) | AU2002236141B2 (ko) |
BR (1) | BR0214925A (ko) |
CA (1) | CA2469702C (ko) |
CY (1) | CY1105814T1 (ko) |
CZ (1) | CZ301283B6 (ko) |
DE (1) | DE60215219T2 (ko) |
DK (1) | DK1458376T3 (ko) |
ES (1) | ES2276910T3 (ko) |
GB (1) | GB0129962D0 (ko) |
HK (1) | HK1073779A1 (ko) |
HU (1) | HU229908B1 (ko) |
IL (2) | IL162391A0 (ko) |
MX (1) | MXPA04005760A (ko) |
NO (1) | NO20042586L (ko) |
NZ (1) | NZ533421A (ko) |
PL (1) | PL206034B1 (ko) |
PT (1) | PT1458376E (ko) |
RU (1) | RU2321398C2 (ko) |
SI (1) | SI1458376T1 (ko) |
SK (1) | SK287510B6 (ko) |
WO (1) | WO2003051354A1 (ko) |
ZA (1) | ZA200404289B (ko) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007109142A2 (en) * | 2006-03-17 | 2007-09-27 | Oregon Health & Science University | M3 muscarinic receptor antagonists for treating tumors |
CN101084891A (zh) * | 2007-06-29 | 2007-12-12 | 北京本草天源药物研究院 | 一种用于口服的达非那新或其药用盐的药物制剂 |
CZ300895B6 (cs) * | 2008-01-28 | 2009-09-02 | Zentiva, A. S. | Zpusob prípravy Darifenacinu |
US9198904B2 (en) * | 2009-02-04 | 2015-12-01 | Astellas Pharma Inc. | Pharmaceutical composition for oral administration |
CN102048706B (zh) * | 2011-01-12 | 2012-02-22 | 山东创新药物研发有限公司 | 一种氢溴酸达非那新缓释片及制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8906166D0 (en) * | 1989-03-17 | 1989-05-04 | Pfizer Ltd | Therapeutic agents |
GB9518953D0 (en) * | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
-
2001
- 2001-12-14 GB GBGB0129962.7A patent/GB0129962D0/en not_active Ceased
-
2002
- 2002-03-05 CZ CZ20040719A patent/CZ301283B6/cs not_active IP Right Cessation
- 2002-03-05 CN CNB028249364A patent/CN100488505C/zh not_active Expired - Lifetime
- 2002-03-05 DK DK02702623T patent/DK1458376T3/da active
- 2002-03-05 WO PCT/IB2002/000664 patent/WO2003051354A1/en active IP Right Grant
- 2002-03-05 EP EP02702623A patent/EP1458376B1/en not_active Expired - Lifetime
- 2002-03-05 CA CA2469702A patent/CA2469702C/en not_active Expired - Lifetime
- 2002-03-05 BR BR0214925-7A patent/BR0214925A/pt active Search and Examination
- 2002-03-05 SI SI200230464T patent/SI1458376T1/sl unknown
- 2002-03-05 ES ES02702623T patent/ES2276910T3/es not_active Expired - Lifetime
- 2002-03-05 RU RU2004121780/15A patent/RU2321398C2/ru active
- 2002-03-05 MX MXPA04005760A patent/MXPA04005760A/es active IP Right Grant
- 2002-03-05 PL PL369426A patent/PL206034B1/pl unknown
- 2002-03-05 KR KR1020047009000A patent/KR100889086B1/ko active IP Right Grant
- 2002-03-05 PT PT02702623T patent/PT1458376E/pt unknown
- 2002-03-05 JP JP2003552287A patent/JP2005516925A/ja not_active Withdrawn
- 2002-03-05 IL IL16239102A patent/IL162391A0/xx unknown
- 2002-03-05 SK SK250-2004A patent/SK287510B6/sk not_active IP Right Cessation
- 2002-03-05 NZ NZ533421A patent/NZ533421A/en not_active IP Right Cessation
- 2002-03-05 DE DE60215219T patent/DE60215219T2/de not_active Expired - Lifetime
- 2002-03-05 AT AT02702623T patent/ATE341323T1/de active
- 2002-03-05 AU AU2002236141A patent/AU2002236141B2/en not_active Expired
- 2002-03-05 HU HU0402625A patent/HU229908B1/hu not_active IP Right Cessation
- 2002-09-26 US US10/256,420 patent/US20030130338A1/en not_active Abandoned
-
2004
- 2004-06-01 ZA ZA2004/04289A patent/ZA200404289B/en unknown
- 2004-06-07 IL IL162391A patent/IL162391A/en active IP Right Grant
- 2004-06-18 NO NO20042586A patent/NO20042586L/no not_active Application Discontinuation
-
2005
- 2005-07-25 HK HK05106309.8A patent/HK1073779A1/xx not_active IP Right Cessation
-
2006
- 2006-11-30 CY CY20061101729T patent/CY1105814T1/el unknown
-
2007
- 2007-07-19 US US11/880,006 patent/US20070264333A1/en not_active Abandoned
-
2009
- 2009-03-04 US US12/397,433 patent/US8748476B2/en not_active Expired - Lifetime
- 2009-10-30 JP JP2009250519A patent/JP2010024244A/ja not_active Withdrawn
-
2013
- 2013-07-11 JP JP2013145736A patent/JP2013199506A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013199506A (ja) | 処置方法 | |
US20040192784A1 (en) | Combination of a betablocker and a cholesterol-lowering agent | |
Yasuda et al. | Review of the pharmacological properties and clinical usefulness of muscarinic agonists for xerostomia in patients with Sjögren’s syndrome | |
KR20010110798A (ko) | 신경퇴화의 치료방법 | |
JP2000508618A (ja) | 口腔乾燥症の処置におけるコリンエステラーゼ阻害剤の使用 | |
DE69923982T2 (de) | Verwendung einer zusammensetzung enthaltend eine assoziation eines angiotensin ii at1 rezeptor antagonists und indomethacin zur herstellung eines arzneimittels zur behandlung von kronischen glomerulonephriten | |
RU2810844C2 (ru) | Композиция для применения в предупреждении и/или лечении патологий слизистой оболочки мочеполовой системы | |
Iversen et al. | Direct diabetogenic effect of diltiazem? | |
KR970032865A (ko) | 허혈성 심질환으로 고생하는 환자의 경색크기를 감소하기 위한 방법 | |
JP2023540355A (ja) | 神経障害性疼痛の局所治療において使用するメピラミン | |
US20050209339A1 (en) | Methods for the treatment of sinusitis | |
AU2003259464A1 (en) | Use of a quinazoline derivative for treating lower urinary tract symptoms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
N231 | Notification of change of applicant | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130221 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140221 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20150224 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160218 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170302 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20190227 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20200227 Year of fee payment: 12 |